title: HIV-1 envelope accessible surface and polarity: clade, blood, and brain.
abstract: The human immunodeficiency virus type-1 (HIV-1) gp160 (gp120-gp41 complex) trimer envelope (ENV) protein is a potential vaccine candidate for HIV/AIDS. HIV-1 vaccine development has been problematic and charge polarity as well as sequence variation across clades may relate to the difficulties. Further obstacles are caused by sequence variation between blood and brain-derived sequences, since the brain is a separate compartment for HIV-1 infection. We utilize a threedimensional residue measure of solvent exposure, accessible surface area (ASA), which shows that major segments of gp120 and gp41 known structures are solvent exposed across clades. We demonstrate a large percent sequence polarity for solvent exposed residues in gp120 and gp41. The range of sequence polarity varies across clades, blood, and brain from different geographical locations. Regression analysis shows that blood and brain gp120 and gp41 percent sequence polarity range correlate with mean Shannon entropy. These results point to the use of protein modifications to enhance HIV-1 ENV vaccines across multiple clades, blood, and brain. It should be noted that we do not address the issue of protein glycosylation here; however, this is an important issue for vaccine design and development.
  
  
  BACKGROUND
  HIV-1 - human immunodeficiency virus type 1, AIDS - acquired immunodeficiency syndrome, ENV - envelope, gp160 - 160,000d glycoprotein, gp120 - 120,000d glycoprotein, gp41 - 41,000d glycoprotein, LANL - Los Alamos National Laboratories, PDB - Protein Data Bank, HVTN - STEP HIV vaccine trial, AA - amino acids, MSA - multiple sequence alignment, ASA - accessible surface area, SNPs- single nucleotide polymorphisms, HAART - Highly Active Antiretroviral Therapy, CCR5 - C-C chemokine receptor type 5, CNS - central nervous system, HIVE - HIV encephalitis, P - polarity, NP - non-polarity, CTL - cytotoxic T lymphocyte, NIAID - National Institute of Allergy and Infectious Diseases.
authors.forename: Gopichandran
authors.initials: G
authors.lastname: Sowmya
authors.forename: Gunasagaran
authors.initials: G
authors.lastname: Shamini
authors.forename: Sathyanarayanan
authors.initials: S
authors.lastname: Anita
authors.forename: Meena
authors.initials: M
authors.lastname: Sakharkar
authors.forename: Venkat
authors.initials: V
authors.lastname: Mathura
authors.forename: Hector
authors.initials: H
authors.lastname: Rodriguez
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Levine
authors.forename: Elyse
authors.initials: E
authors.lastname: Singer
authors.forename: Deborah
authors.initials: D
authors.lastname: Commins
authors.forename: Charurut
authors.initials: C
authors.lastname: Somboonwit
authors.forename: John T
authors.initials: JT
authors.lastname: Sinnott
authors.forename: Harcharan S
authors.initials: HS
authors.lastname: Sidhu
authors.forename: Ganapathy
authors.initials: G
authors.lastname: Rajaseger
authors.forename: Peter Natesan
authors.initials: PN
authors.lastname: Pushparaj
authors.forename: Pandajarasamme
authors.initials: P
authors.lastname: Kangueane
authors.forename: Paul
authors.initials: P
authors.lastname: Shapshak